drugset / Trial / NCT04684563
huCART19-IL18 in CD19+ Cancers
Phase 1
Active not recruiting
72 enrolled
University of Pennsylvania
BlueWhale Bio (Cohort D only) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.
Timeline
- Start
- 2021-05-06
- Primary completion
- 2036-05
- Completion
- 2036-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | huCART19-IL18 | Cell therapy | 700000 cells | Intravenous |
| Subject | huCART19-IL18 | Cell therapy | 3e+06 cells | Intravenous |
| Subject | huCART19-IL18 | Cell therapy | 7e+06 cells | Intravenous |
| Subject | huCART19-IL18 | Cell therapy | 3e+07 cells | Intravenous |
| Subject | huCART19-IL18 | Cell therapy | 7e+07 cells | Intravenous |
| Subject | huCART19-IL18 | Cell therapy | 3e+08 cells | Intravenous |